Cargando…

Dupilumab Improves Outcomes in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma Irrespective of Baseline Asthma Characteristics

PURPOSE: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2 inflammatory disease frequently coexisting with other type 2 conditions including asthma and non-steroidal anti-inflammatory drug-exacerbated respiratory disease (NSAID-ERD). Coexisting asthma leads to increased CRS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Busse, William Walter, Pavord, Ian Douglas, Siddiqui, Shahid, Khan, Asif Hameed, Praestgaard, Amy, Nash, Scott, Jacob-Nara, Juby Anne, Rowe, Paul Jonathan, Deniz, Yamo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Rapid Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122472/ https://www.ncbi.nlm.nih.gov/pubmed/37096015 http://dx.doi.org/10.2147/JAA.S391896

Ejemplares similares

Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
por: Hellings, Peter W., et al.
Publicado: (2022)

Rapid and Continuing Improvements in Nasal Symptoms with Dupilumab in Patients with Severe CRSwNP
por: Bachert, Claus, et al.
Publicado: (2022)

Improvement in Health-Related Quality of Life with Dupilumab in Patients with Moderate-to-Severe Asthma with Comorbid Chronic Rhinosinusitis with/without Nasal Polyps: An Analysis of the QUEST Study
por: Hopkins, Claire, et al.
Publicado: (2022)

Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trials
por: Bachert, Claus, et al.
Publicado: (2022)

Health-Related Quality of Life Impairment Among Patients with Severe Chronic Rhinosinusitis with Nasal Polyps in the SINUS-24 Trial
por: Maspero, Jorge F, et al.
Publicado: (2023)

AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps
por: Siddiqui, Shahid, et al.
Publicado: (2022)

Improvement in patient‐reported “taste” and association with smell in dupilumab‐treated patients with severe chronic rhinosinusitis with nasal polyps from the SINUS‐24 and SINUS‐52 trials
por: Peters, Anju T., et al.
Publicado: (2022)

Dupilumab provides early and durable improvement of symptoms in patients with chronic rhinosinusitis with nasal polyps
por: Gevaert, Philippe, et al.
Publicado: (2023)

Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL(−1)
por: Rabe, Klaus F., et al.
Publicado: (2022)

The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan
por: Fujieda, Shigeharu, et al.
Publicado: (2020)

Long-term efficacy of dupilumab in severe asthma by baseline oral corticosteroid dose
por: Domingo, Christian, et al.
Publicado: (2023)

Impact of exacerbation history on long-term efficacy of dupilumab in patients with asthma
por: Corren, Jonathan, et al.
Publicado: (2023)

Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils
por: Bleecker, Eugene R., et al.
Publicado: (2023)

Dupilumab leads to better-controlled asthma and quality of life in children: the VOYAGE study
por: Fiocchi, Alessandro G., et al.
Publicado: (2023)

Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
por: Corren, Jonathan, et al.
Publicado: (2023)

Dupilumab-Treated Patients with Asthma in the Real World: The RAPID Global Registry
por: Gall, Rebecca, et al.
Publicado: (2023)

Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation
por: Hanania, Nicola A, et al.
Publicado: (2022)

Dupilumab is effective in type 2‐high asthma patients receiving high‐dose inhaled corticosteroids at baseline
por: Bourdin, Arnaud, et al.
Publicado: (2020)

Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status
por: Fujieda, Shigeharu, et al.
Publicado: (2021)

Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma
por: Papi, Alberto, et al.
Publicado: (2022)

Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design
por: De Prado Gomez, Lucia, et al.
Publicado: (2023)

Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps
por: Hopkins, Claire, et al.
Publicado: (2021)

Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference?
por: Al-Ahmad, Mona, et al.
Publicado: (2023)

Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma
por: Corren, Jonathan, et al.
Publicado: (2021)

Dupilumab efficacy in adolescents with uncontrolled, moderate‐to‐severe asthma: LIBERTY ASTHMA QUEST
por: Maspero, Jorge F., et al.
Publicado: (2021)

Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results
por: Bachert, Claus, et al.
Publicado: (2023)

Real-life effects of dupilumab in patients with severe type 2 asthma, according to atopic trait and presence of chronic rhinosinusitis with nasal polyps
por: Pelaia, Corrado, et al.
Publicado: (2023)

The burden of chronic rhinosinusitis with nasal polyps and its relation to asthma in Finland
por: Toppila‐Salmi, Sanna, et al.
Publicado: (2022)

Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation
por: Busse, William W., et al.
Publicado: (2021)

Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma
por: Castro, Mario, et al.
Publicado: (2020)

Therapeutic Potential of Dupilumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Evidence to Date
por: Kim, Jean, et al.
Publicado: (2020)

The Role of Dupilumab in Severe Asthma
por: Ricciardolo, Fabio Luigi Massimo, et al.
Publicado: (2021)

Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis
por: Tanaka, Shunya, et al.
Publicado: (2022)

Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review
por: Nitro, Letizia, et al.
Publicado: (2022)

Dupilumab Efficacy in Patients Stratified by Baseline Treatment Intensity and Lung Function
por: Pavord, Ian D, et al.
Publicado: (2020)

Chronic rhinosinusitis with and without nasal polyps and asthma: Omalizumab improves residual anxiety but not depression
por: Vogt, Florian, et al.
Publicado: (2021)

Chronic rhinosinusitis with nasal polyps and allergic rhinitis as different multimorbid treatable traits in asthma
por: Castillo, José Antonio, et al.
Publicado: (2023)

Dupilumab: a novel treatment for asthma
por: Vatrella, Alessandro, et al.
Publicado: (2014)

Severe pediatric asthma therapy: Dupilumab
por: Ferrante, Giuliana, et al.
Publicado: (2022)

WITHDRAWN: Dupilumab: A review of potential in the treatment of Chronic rhinosinusitis with nasal polyps (CRSwNP)
por: Sree Sudha, T.Y., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_a39b3lp8ptblfp837ip35c4t3a